Argenx to Buy Forte Biosciences for $2.2 Billion as Immunology Dealmaking Spreads
Updated
Updated · STAT · Jul 27
Argenx to Buy Forte Biosciences for $2.2 Billion as Immunology Dealmaking Spreads
3 articles · Updated · STAT · Jul 27
Summary
$2.2 billion in cash will buy Forte Biosciences, with Argenx offering $77 a share for the Dallas-based biotech.
That price is a 41% premium to Forte's Friday close and gives Argenx another asset as it expands its immunology pipeline.
Argenx has built momentum in immunology through Vyvgart, whose approvals in generalized myasthenia gravis and CIDP have driven steady sales growth as its label widened.
The takeover extends a broader biotech acquisition run, with even midsize drugmakers increasingly pursuing smaller targets to replenish pipelines.